An Australian study published in The Lancet Digital Health evaluates BRAIx, an AI tool that predicts a woman's risk of developing breast cancer within four years after a clear mammogram to enhance screening decisions.

BRAIx could enable personalized screening by prioritizing high-risk women for closer monitoring or advanced imaging (MRI or contrast-enhanced mammography) while allowing low-risk women to space out check-ups, potentially improving early detection and reducing anxiety and unnecessary testing.

Findings suggest BRAIx can help determine which women should undergo additional tests, potentially enabling earlier detection of cancers that standard mammography might miss.

Development and deployment face challenges, including obtaining FDA approval, reimbursement considerations, and ensuring equitable access across diverse populations and imaging systems.

A major caveat is that prospective studies are needed to confirm real-world impact on mortality, quality of life, cost-effectiveness, and clinical outcomes before clinical use.

Future steps involve larger-scale validation, real-world implementation data, and ongoing assessment of AI performance to ensure fairness and effectiveness across populations.

Experts emphasize BRAIx is a decision-support aid designed to augment, not replace, clinical judgment, with necessary human oversight over sensitivity and specificity.

Limitations include a four-year horizon, potential loss-to-follow-up bias, need for more diverse populations, and lack of data on mortality or changes in biopsy/intervention rates.

The piece is republished from The Conversation and includes funding disclosures for the authors.

Funding disclosures note support from Cancer Australia, the Medical Research Future Fund, and the National Breast Cancer Foundation.

The study suggests potential cost-neutral implementation and calls for broader validation and assessment of integration into routine screening programs.

BRAIx received about $5 million from Australia’s Medical Research Future Fund, with plans for a smaller prospective real-time study and a goal to roll out BRAIx within five years.